The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy, according to Taiho Pharmaceutical Co., Ltd., the manufacturer of the oral agent.
TAS-102 was previously approved in the Japan for the treatment of patients with colorectal cancer (CRC). In the United States, TAS-102 has approved indications for CRC and gastric/GEJ cancer.
Arkenau H-T, Tabernero J, Shitara K, et al. TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Presented at: 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. LBA25.
... to read the full story